文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients.

作者信息

Welén Karin, Rosendal Ebba, Freyhult Eva, Oh William K, Gisslén Magnus, Ahlm Clas, Connolly Anne-Marie Fors, Överby Anna K, Josefsson Andreas

机构信息

Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Department of Clinical Microbiology, Umeå University, Umeå, Sweden.

出版信息

Eur Urol. 2022 Jun;81(6):e143-e144. doi: 10.1016/j.eururo.2022.02.016. Epub 2022 Feb 23.

DOI:10.1016/j.eururo.2022.02.016
PMID:35248411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8864103/
Abstract
摘要

相似文献

[1]
Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients.

Eur Urol. 2022-6

[2]
Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients.

Eur Urol. 2022-6

[3]
Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93.

Eur Urol. 2022-5

[4]
Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-293.

Eur Urol. 2022-5

[5]
Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012.

Eur Urol. 2022-6

[6]
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.

Eur Urol. 2022-3

[7]
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?

Eur Urol. 2022-4

[8]
Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.

Eur Urol. 2021-2

[9]
Reply to M.V. Meng's Letter to the Editor re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9 and P.L. Steinberg et al. re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9. Eur Urol 2007;51:572-3.

Eur Urol. 2007-5

[10]
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.

Eur Urol. 2016-3

本文引用的文献

[1]
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.

JNCI Cancer Spectr. 2022-5-2

[2]
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.

Eur Urol. 2022-3

[3]
Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.

Cureus. 2021-12-25

[4]
Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer.

Scand J Urol. 2022-4

[5]
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.

JAMA Netw Open. 2021-11-1

[6]
Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review.

Crit Rev Oncol Hematol. 2021-11

[7]
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.

Front Med (Lausanne). 2021-7-19

[8]
Does androgen deprivation therapy protect against severe complications from COVID-19?

Ann Oncol. 2020-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索